Acne Response Intensive

Acne Response Intensive
Cyclacel PS reaches agreement with FDA for Phase 3 trial in aMl sapacitabine Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing therapies of oral target different stages of cell cycle control for treating cancer and other serious diseases, today announced it has reached agreement with the Food and Drug Administration of USA (FDA) regarding a Special Protocol Assessment (SPA) in the development of a major phase 3 trial for the company ...